Menu
Search
|

Menu

Close
X

Immutep Ltd IMMP.OQ (NASDAQ Stock Exchange Global Market)

1.78 USD
+0.01 (+0.56%)
As of Feb 17
chart
Previous Close 1.77
Open 1.80
Volume 3,672
3m Avg Volume 11,413
Today’s High 1.80
Today’s Low 1.77
52 Week High 3.23
52 Week Low 1.25
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Russell Howard
Non-Executive Chairman of the Board, Since 2017
Salary: $90,000.00
Bonus: --
Marc Voigt
Chief Executive Officer, Executive Director, Since 2016
Salary: $328,802.00
Bonus: --
Pete Meyers
Non-Executive Deputy Chairman of the Board, Since 2017
Salary: --
Bonus: --
Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary, Since 2016
Salary: $180,384.00
Bonus: --
Frederic Triebel
Chief Scientific Officer & Chief Medical Officer, Since 2014
Salary: $245,616.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Plaza Building, L 12 95 Pitt St
SYDNEY   NSW   2000

Phone: +612.83157003

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

SPONSORED STORIES